{
    "clinical_study": {
        "@rank": "72365", 
        "acronym": "VALOR-HCV", 
        "arm_group": {
            "arm_group_label": "Sofosbuvir+RBV 12 weeks", 
            "arm_group_type": "Experimental", 
            "description": "Participants will receive sofosbuvir+RBV for 12 weeks."
        }, 
        "brief_summary": {
            "textblock": "This study will examine the safety, tolerability, and antiviral efficacy of sofosbuvir\n      (SOF)+ribavirin (RBV) in treatment-naive and treatment-experienced United States Veterans\n      with compensated cirrhosis and genotype 2 HCV infection."
        }, 
        "brief_title": "Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C Virus Infection", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C", 
                "Fibrosis", 
                "Virus Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Willing and able to provide written informed consent.\n\n          -  Treatment-naive or treatment-experienced adult, U.S. Veteran\n\n          -  Chronic genotype 2 (GT2) HCV infection Classified as:\n\n               -  Eligible for treatment with interferon (IFN)-based therapy\n\n               -  Ineligible for IFN treatment\n\n               -  Intolerant to IFN.\n\n          -  Cirrhosis determination\n\n          -  Laboratory parameters within prespecified ranges at screening:\n\n          -  A negative serum pregnancy test is required for females of childbearing potential\n\n          -  Males and females of childbearing potential who engage in heterosexual intercourse\n             must agree to use protocol specified method(s) of contraception\n\n          -  Lactating females must agree to discontinue nursing before study drug is\n             administered.\n\n          -  Males must agree to refrain from sperm donation from the date of screening until at\n             least 7 months after the last dose of RBV, or 90 days after their last dose of study\n             drug if not taking RBV.\n\n          -  Must be able to comply with the dosing instructions for study drug administration and\n             able to complete the study schedule of assessments.\n\n          -  Must be of generally good health as determined by the Investigator.\n\n        Exclusion Criteria:\n\n          -  Current participation in an interventional clinical trial.\n\n          -  Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV).\n\n          -  History of any other clinically significant chronic liver disease (e.g.,\n             hemochromatosis; Wilson's disease; \u03b11-antitrypsin deficiency), except NASH.\n\n          -  Decompensated liver\n\n          -  History of hemoglobinopathies\n\n          -  Contraindication or hypersensitivity to RBV\n\n          -  History or current evidence of any condition, therapy, laboratory abnormality or\n             other circumstance that might confound the results of the study, or interfere with\n             the participation for the full duration of the study, such that it is not in the best\n             interest of the individual to participate.\n\n          -  Clinically significant ECG abnormality at screening.\n\n          -  History of solid organ transplantation.\n\n          -  Presence of hepatocellular carcinoma (HCC) Malignancy within 5 years prior to\n             screening, with the exception of specific cancers that are entirely cured by surgical\n             resection (basal cell skin cancer and prostate cancer in remission). Individuals\n             under evaluation for possible malignancy are not eligible.\n\n          -  Prior treatment with an NS5B polymerase inhibitor.\n\n          -  Chronic use of systemic immunosuppressive agents or immunomodulatory agents (e.g.,\n             prednisone equivalent > 10 mg/day).\n\n          -  Concomitant disallowed as per the Sovaldi Packet Insert.\n\n          -  Known hypersensitivity to the study drug, the metabolites, or formulation excipient.\n\n          -  History of difficulty with blood collection and/or poor venous access for the\n             purposes of phlebotomy.\n\n          -  Use of any prohibited concomitant medications as described in the study protocol\n\n          -  Gastrointestinal disorder or post-operative condition that could interfere with the\n             absorption of the study drug.\n\n          -  Male with pregnant female partner.\n\n          -  In the judgment of the investigator any clinically-relevant drug or alcohol abuse\n             within 12 months of screening that may interfere with treatment, assessment or\n             compliance with the protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02128542", 
            "org_study_id": "GS-US-334-1379"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sofosbuvir+RBV 12 weeks", 
                "description": "Sofosbuvir 400 mg tablet administered orally once daily", 
                "intervention_name": "Sofosbuvir", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Sovaldi\u00ae", 
                    "GS-7977", 
                    "PSI-7977"
                ]
            }, 
            {
                "arm_group_label": "Sofosbuvir+RBV 12 weeks", 
                "description": "Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and \u2265 75 kg = 1200 mg)", 
                "intervention_name": "RBV", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ribavirin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Veterans HCV", 
        "lastchanged_date": "April 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Long Beach", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90822"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90073"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palo Alto", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94394"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92102"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94121"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06520"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33125"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Decatur", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30033"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21201"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64128"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27705"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15240"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75216"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23249"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 4, Multicenter, Open Label Study to Investigate the Efficacy and Safety of an All Oral Combination of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis VALOR-HCV: Veterans Affairs alL Oral Regimen of SOF+RBV in GT2 HCV", 
        "overall_contact": {
            "email": "GS3341379study@gilead.com", 
            "last_name": "Gilead Study Team"
        }, 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Star Seyedkazemi, PharmD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "SVR12 is defined as HCV RNA < the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.", 
                "measure": "Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)", 
                "safety_issue": "No", 
                "time_frame": "Posttreatment Week 12"
            }, 
            {
                "measure": "Incidence of adverse events leading to permanent discontinuation of study drug(s)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 12"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02128542"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "SVR4 is defined as HCV RNA < LLOQ at 4 weeks following the last dose of study drug.", 
                "measure": "Proportion of participants with sustained virologic response (SVR) at 4 weeks after discontinuation of therapy (SVR4)", 
                "safety_issue": "No", 
                "time_frame": "Posttreatment Week 4"
            }, 
            {
                "description": "Viral breakthrough is defined as either:\nHCV RNA \u2265 LLOQ after having previously had HCV RNA < LLOQ while receiving treatment\nHCV RNA \u2265 LLOQ at the last available on-treatment measurement with no subsequent follow-up values", 
                "measure": "Proportion of participants experiencing viral breakthrough", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 12"
            }, 
            {
                "description": "Viral relapse is defined as HCV RNA \u2265 LLOQ during the posttreatment period after having achieved HCV RNA < LLOQ at end of treatment.", 
                "measure": "Proportion of participants experiencing viral relapse", 
                "safety_issue": "No", 
                "time_frame": "Week 12 to Posttreatment Week 12"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}